Denosumab for treating periprosthetic osteolysis; study protocol for a randomized, double-blind, placebo-controlled trial

BACKGROUND: Wear-induced osteolysis is the main factor in reducing the longevity of total hip arthroplasty (THA). The transmembrane Receptor Activator of Nuclear Factor κ B (RANK) and its corresponding ligand RANKL is an important regulator of osteoclast activity and bone resorption and is associate...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Musculoskelet Disord
Päätekijät: Sköldenberg, Olof, Rysinska, Agata, Eisler, Thomas, Salemyr, Mats, Bodén, Henrik, Muren, Olle
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2016
Aiheet:
Study Protocol
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4841945/
https://ncbi.nlm.nih.gov/pubmed/27108405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12891-016-1036-5
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia